Almost a third of all respondents who were aware of their HbA 1c levels were uncontrolled on their current treatment regimen, making them potential candidates for insulin intensification.
The main barriers to insulin intensification reported by T2DM patients on basal insulin were: -Number of daily injections -Difficulties in figuring out the right dosage of bolus insulin for meals -Fear of weight gain.
Insulin intensification regimens with fewer injections, a simple dosing system and reduced risk of weight gain, pain or discomfort, and hypoglycaemia may help patients who are uncontrolled on basal insulin overcome these barriers to intensification and achieve target levels of HbA 1c .
Assessing patient preference for insulin intensification in France Background
Type 2 diabetes mellitus (T2DM) is the most common form of diabetes, accounting for 92% of cases in France. 1, 2 Since 2010, T2DM has been associated with the highest prevalence among all chronic diseases in France, with the number of patients almost doubling in the past decade.
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Inadequate glycaemic control as a result of T2DM is an important issue for patients as it can lead to microvascular complications (eye, nerve and kidney damage) and macrovascular complications (heart disease, stroke and peripheral arterial disease of lower extremities). In France, it has been reported that 42.3% of patients do not achieve good glycaemic control. 4, 5 Consequently,T2DM is the leading cause of blindness, 6 amputation 7 and dialysis in France. 8 In order to achieve adequate glycaemic control, T2DM patients may require treatment intensification with insulin. However, the complexity associated with treatment intensification may create barriers in treatment adherence and subsequent glycaemic control.
Objective
To assess patient-perceived barriers and behaviours related to intensification of treatment in insulin-treated T2DM in France.
Methods

Online study questionnaire
The study participants from France were adults with T2DM diagnosed >6 months ago and receiving insulin for ≥3 months (but not using an insulin pump). 
Results
Demographics
302 people with T2DM from France (59% male, mean age 50 years) completed the survey (Table 1) . The mean duration of T2DM since diagnosis was 11 years and the mean duration of insulin treatment was 6 years. 
34%
Dif cult to gure out the right dose of bolus insulin related to food/meals (n=27)
30%
Weight gain (n=24)
27%
Pain and/or discomfort of injections (n=21)
23%
Risk of hypoglycaemia events (n=18)
15%
Timing of premixed or bolus insulin injections with meals (precise timing, injecting in public places (n=12) 
Patient experience with insulin
The treatment regimens used by the 302 respondents were basal-only insulin 45% (n=137); bolus-only insulin (short-acting) 24% (n=71); basal-bolus insulin 24% (n=73); premix insulin 5% (n=16); other 2% (n=5). More than half of respondents (39/73; 53%) using basal-bolus insulin reported injecting bolus insulin at least 3 or more times a day, in addition to their basal insulin. More than three-quarters of respondents (78%; 237/302) reported ever having a minor (non-severe, self-managed) hypoglycaemic event, of which 46% (111/237) reported events that occurred once a week or more (Figure 1 ). The average number of reported minor hyperglycaemic events per year was 33.9. 32% (98/302) of respondents reported ever having a major (severe) hypoglycaemic event (requiring assistance from another person or medical professional), of which 97% reported at least one occurrence within the past 12 months. Living alone (%) 24
Have children (%) 74
Married or partnered (%) 73
Have a college or university degree (%) 44
In paid employment or self-employed (%) 49
Monthly household income before tax <2.000€ (%) 25 BMI, body mass index; T2DM, type 2 diabetes mellitus Barriers to insulin intensification 31% (42/137) of respondents on basal-only insulin reported having tried another type of insulin regimen (premixed insulin, basal-bolus insulin, GLP-1 agonist added to basal insulin or other treatment), but switching back to their initial treatment. A total of 57% (79/137) of respondents currently on basal-only insulin would hesitate to intensify treatment through adding bolus insulin or switching to premix insulin. The main reasons for this included the number of daily injections (42%), difficulty in determining the correct dose of bolus insulin in relation to meals (34%) and fear of weight gain (30%; Figure 3 ).
Discussion
This study provides insight into patient-perceived barriers and behaviours to treatment intensification for insulin-treated T2DM patients in France. Number of daily injections, difficulties figuring out the optimal dose of bolus insulin for meals and fear of weight gain were the most commonly cited reasons for hesitation to intensify treatment amongst those on basal insulin.
A potential limitation of the study is that recruitment required respondents to have an email address and an adequate degree of computer literacy. This may have introduced selection bias, although it should be noted that the patient panels claimed to be reflective of the general diabetes population; and, according to the World Bank there is 83.8% internet penetration in the French population. Additionally, the self-reported nature of the online questionnaire limited opportunities for data checks. This is in line with results from a wider European dataset, which showed that respondents on basal-only insulin who had previously tried more intensive regimens cited difficulty in handling multiple daily injections, risk of weight gain and risk of hypoglycaemic events as the reasons for reverting to basal-only insulin treatments.
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Furthermore, according to a patient-preference study of different aspects of T2DM therapy, patients had the highest willingness-to-pay values for reductions in number of daily injections, avoidance of weight gain and hypoglycaemic events.
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Factors such as increased risk of weight gain and hypoglycaemia, polypharmacy and complexity of treatment regimens have been shown to reduce adherence to T2DM medication, 12 which is a significant predictor of glycaemic control.
13,14
More convenient and patient-friendly treatments with a lower number of daily injections, lower risk of weight gain and hypoglycaemia, and simpler dosing systems could be wellperceived by T2DM patients and might help overcome barriers to insulin intensification.
